{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-005696","form_type":"8-K","ticker":"JYNT","cik":"0001612630","company_name":"JOINT Corp","filed_at":"2023-09-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.555514+00:00","generated_at":"2026-06-10T19:05:20.986460+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Joint Corp. Q2 prelim: rev $29.3M (+18%), Adj EBITDA $3.2M (+23%), cuts FY guidance","bullets":["Revenue $29.3M (+18% YoY); operating loss improved to $0.375M from $1.3M loss in Q2 2022.","Adjusted EBITDA $3.2M (+23% YoY); system-wide sales $120.1M (+13%); comp sales +5%.","FY 2023 revenue guidance cut to $115-118M from $123-128M; Adj EBITDA cut to $11-12.5M from $12.5-14M.","Plans to cull ~10% of corporate clinic portfolio via accretive transactions to improve profitability.","Cash $13.6M; opened 26 new clinics in Q2; total clinics 890 at quarter end, 911 as of Sept 12."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-005696","json":"https://secwatch.observer/filing/0001171843-23-005696.json","markdown":"https://secwatch.observer/filing/0001171843-23-005696.md","text":"https://secwatch.observer/filing/0001171843-23-005696.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1612630/000117184323005696/0001171843-23-005696-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1612630/000117184323005696/f8k_091323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T19:05:20.986460+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"da7e907416ac17907eba3f9d3a83d9f20917ee02","claim":"JOINT Corp reported the second quarter ended June 30, 2023 results: revenue $29.3 million. Guidance lowered.","evidence_excerpt":"its preliminary financial results for the second quarter ended June 30, 2023. Preliminary Financial Highlights: Q2 2023 Compared to Q2 2022 Grew preliminary revenue 18% to $29.3 million. Reported preliminary operating loss of $375,000, compared to $1.3 million. Reported preliminary loss before income tax expense of $481,000, compared to $1.3 million. Increased","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1612630/000117184323005696/0001171843-23-005696-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$29.3 million"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}